Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AngioGuard Inc.

Division of Cardinal Health Inc./Cordis Corp.

Latest From AngioGuard Inc.

Start-Up News September 2007

TheraCardia has a portfolio of natural biopolymers that it will develop for stents; initially, for stent coatings, and soon, a bioabsorbable stent that avoids inflammation and contributes to endothelization, without the need for a drug. Surgeon-founded Aragon Surgical will develop a platform of products to make surgeries faster and safer. Intelect Medical is developing new neurostimulation devices that, it believes, offer advances over the devices of predecessors. It's initial target application is traumatic brain injury.
Platform Technologies

Guidant Pioneers Stents' Move North to Carotids

Stenting moves from coronaries to carotids to do for stroke what these devices did for heart attacks. This new endovascular approach has surgeons switching, not fighting.
Medical Device Clinical Trials

CardioMEMS Inc.

CardioMEMS has developed a wireless, implantable pressure sensor, to help physicians "watch and wait" after endovascular AAA repair. The same technology forms the foundation for a future continuous monitoring platform in congestive heart failure.
Medical Device

Embolic Protection: Better Outcomes Not Enough

For 20 years, interventional cardiologists denied the need for embolic protection devices, considering embolic events to generally be the infrequent results of poor technique. Nevertheless, recent data has revealed embolization as a potentially serious and relatively common event during percutaneous coronary interventions. While embolic protection devices have been shown to dramatically reduce embolic complications, physician adoption is slow. Several companies are developing different approaches to protect against embolization, recognizing that better patient data alone isn't enough to convince interventionalists to employ these devices.
Medical Device Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Cardiovascular
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Cardinal Health Inc.
  • Senior Management
  • Mark Maciejewski, Pres. & CEO
    Thomas Borillo, VP, Sales & Mktg.
    Gregg Sutton, VP, R&D
  • Contact Info
  • AngioGuard Inc.
    Phone: (612) 543-6800
    13355 10th Ave N
    Suite114
    Plymouth, MI
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register